Blog

Akihiro Ohba: Trastuzumab Deruxtecan in HER 2–Expressing Biliary Tract Cancer

Photo from Akihiro Ohba/X

Aug 12, 2024, 04:06

Akihiro Ohba: Trastuzumab Deruxtecan in HER 2–Expressing Biliary Tract Cancer

Akihiro Ohba, Medical Oncologist at Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, posted on X about recent paper by him as first author, titled “Trastuzumab Deruxtecan in HER2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial” published on Journal of Clinical Oncology.

Authors: Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Takuji Okusaka.

“Trastuzumab Deruxtecan in HER 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial | Journal of Clinical Oncology.”

Source: Akihiro Ohba/X

Akihiro Ohba Biliary tract cancer cancer Chigusa Morizane Journal of Clinical Oncology Makoto Ueno Masafumi Ikeda National Cancer Center Hospital OncoDaily Oncology Pancreatic Oncology Satoshi Kobayashi Takuji Okusaka Tokyo trastuzumab Yasuyuki Kawamoto Yoshito Komatsu

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage